Arine, a San Francisco, CA-based medication intelligence company, raised $29M Series B funding.
The round was led by 111° West Capital, with participation from MBX Capital, New Leaf Venture Partners, Katalyst Ventures and Super Capital Group.
The company intends to use the funds to advance the capabilities of its platform to enable value-based care at scale, and to expand its offerings to channel partners across the value-based care continuum.
Led by CEO Yoona Kim, Arine is a medication intelligence company that provides a platform which enables clients to devise appropriate, just-in-time interventions to optimize medication therapy for their populations.
Since the company’s launch in 2019, Arine has acquired health plan clients such as national, Blue Cross/Blue Shield, Medicaid, and Medicare Advantage plans, including special needs plans. The company has also expanded its staff to nearly 100 employees.
FinSMEs
17/08/2022